Atopic Dermatitis as a Paradoxical Effect of Secukinumab for the Treatment of Psoriasis

In the therapeutic arsenal to treat moderate to severe psoriasis, the new agents are secukinumab and ustekinumab, which are fully human monoclonal antibodies, directed against IL-17A and IL-12/23, respectively, which have been shown to be effective and safe in several studies. Their side effects are...

Descripción completa

Detalles Bibliográficos
Autores principales: Mendes Roncada, Eduardo V., Brambilla, Victoria Romanini, Freitas Filitto, Beatriz, Genta, Mariana Pirajá, Morgado de Abreu, Marilda Ap. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2021
Materias:
Single Case
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8299393/
https://www.ncbi.nlm.nih.gov/pubmed/34326727
http://dx.doi.org/10.1159/000513467

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8299393/
https://www.ncbi.nlm.nih.gov/pubmed/34326727
http://dx.doi.org/10.1159/000513467

Ejemplares similares